Friday, 20 November 2026Read the signal. Shape what comes next.
Higher Ed Signal
Get the Signal Brief
Aerial view of the Technical University of Munich campus and surrounding city blocks, with the main university buildings and green spaces visible.

Institutional development · Research, innovation and assessment · Germany

TUM spotlights radiopharmaceutical patented with its hospital for imaging prostate cancer

The Technical University of Munich says a radiopharmaceutical developed and patented at TUM and its university hospital improves visualisation of prostate tumour lesions and supports precise diagnosis.

Photo: Maximilian Dörrbecker ( Chumwa ) / Wikimedia Commons, CC BY-SA 2.5

Why it matters: TUM and TUM University Hospital, where the agent was developed and patented, report a diagnostic tool the university says supports precise prostate cancer diagnosis.

The Technical University of Munich (TUM) reported that a radiopharmaceutical was developed and patented at TUM and TUM University Hospital.

According to TUM, the agent allows tumour lesions to be visualised better and supports precise diagnosis of prostate cancer.

The university notes that about 1.5 million people around the world receive a prostate cancer diagnosis each year.

Editor’s view

Scott James, Research and Innovation Editor

The agent was developed and patented at TUM and TUM University Hospital; if it performs as the university describes, it would support better visualisation of tumour lesions in a disease diagnosed in around 1.5 million people a year.

Keep reading

See all